
Novo Nordisk A/S
- Jurisdiction
Denmark - LEI
549300DAQ1CVT6CXN342 - ISIN
US6701002056 (NVO )- Sectors
Scores
- Fair value (Benjamin Graham formula)
-
€62.90 24.3% undervalued - Financial strength (Piotroski F-Value)
-
4
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
6
/ 7
Profile
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. Read full profile
Fundamentals
- Net revenue
€41.79B - Gross margin
83.9% - EBIT
€19.14B - EBIT margin
45.8% - Net income
€14.88B - Net margin
35.6%
Statement period: - (published )
Estimates
Fiscal Year | Net revenue | Net income |
---|---|---|
|
| |
|
| |
|
|
Stock price
Dividends
- Last dividend amount
-
$0.58 - Ex date
-
- Payment date
-
- Dividend payout ratio
-
45.6%
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Congress transactions
Name | Transaction date | Value |
---|---|---|
Val Hoyle | September 12, 2025 | $1.00K–$15.00K |
Lisa McClain | September 12, 2025 | $1.00K–$15.00K |
Marjorie Greene | August 29, 2025 | $1.00K–$15.00K |
Marjorie Greene | August 20, 2025 | $15.00K–$50.00K |
Scott Franklin | August 14, 2025 | $16.00K–$65.00K |
Earnings Calls
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
Peter Brown |
|
|
|
Sell |
James Anderson |
|
|
|
Buy |
Earnings Calls
Latest earnings call: May 3, 2024 (Q1 2024)